Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Jubilant Pharmova Gains 5%; BSE HEALTHCARE Index Up 0.5%
Tue, 27 Aug 10:40

Jubilant Pharmova Gains 5%; BSE HEALTHCARE Index Up 0.5%Image source: Eoneren/www.istockphoto.com

Jubilant Pharmova share price has zoomed 5% and is presently trading at Rs 945.0.

Meanwhile, the BSE HEALTHCARE index is at 42,383.7 (up 0.5%).

Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 2.4%) and ALKEM LABORATORIES (up 2.2%).

ALEMBIC PHARMA (down 1.2%) and MAX HEALTHCARE INSTITUTE (down 0.7%) are among the top losers today.

Over the last one year, Jubilant Pharmova has moved up from Rs 462.4 to Rs 945.0, registering a gain of Rs 482.7 (up 104.4%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,383.7, registering a gain of 50.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 131.5%), Glenmark Pharma (up 126.3%) and SUVEN PHARMACEUTICALS (up 106.8%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,670.8 .

The top losers among the BSE Sensex today are Bajaj Finserv (down 1.2%) and JSW Steel (down 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.

In the meantime, NSE Nifty is at 24,998.4 (down 0.1%). BPCL and Bajaj Finserv are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,670.8, registering a gain of 16,237.5 points (up 24.8%).

Jubilant Pharmova Financial Update...

Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.

For the year ended March 2024, Jubilant Pharmova reported 212.0% increase in net profit to Rs 727 million compared to net loss of Rs 649 million during FY23. Revenue of the company grew 6.7% to Rs 67,029 million during FY24.

The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 28.8.


Equitymaster requests your view! Post a comment on "Jubilant Pharmova Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!